IBM’s 0.7nm Chip Lands Just as the Market Asks: Where’s the Revenue?

IBM capped the week with a 3.63% gain to €235.40, a move that pushed its weekly advance to roughly 8.5% and brought the stock tantalisingly close to a critical technical threshold. The catalyst was a chip breakthrough that rewrites the physical limits of semiconductor design — but the rally still leaves shares more than 19% below their June peak of €292.85, underscoring a deeper tension between technological promise and commercial reality.

The company unveiled a validated architecture at 0.7 nanometres, or seven ångströms, using a technique called Nanostack that stacks transistors vertically rather than shrinking them laterally. The performance numbers are eye-catching: a single AI accelerator built on the process could deliver around 7,000 TOPS, compared with roughly 1,500 TOPS for today’s chips. Training cycles for frontier models would compress from three months to about two weeks, and energy efficiency improves by up to 70% over IBM’s own 2-nanometre node. SRAM scaling, a metric that had stagnated for years, jumps 40% — the biggest leap in more than a decade.

Yet a caveat hangs over the announcement: IBM no longer manufactures its own chips. Commercial production is estimated to be at least five years away, and no foundry partner has been named. The underlying nanosheet architecture is already used by Samsung, Intel and TSMC, which could ease adoption, but for now the technology remains a roadmap item rather than a revenue driver.

That gap between promise and delivery is precisely what investors are wrestling with. IBM’s generative AI order backlog has swelled to €12.5 billion, a figure that signals strong customer intent. But the consulting division — the group’s largest revenue segment — grew just 1% in constant currency during the first quarter. The question haunting the stock is whether that pipeline will convert into billable work, or whether AI tools will cannibalise the very services that have historically funded IBM’s transformation.

Should investors sell immediately? Or is it worth buying IBM?

The bull case rests on the software and infrastructure units, which posted 11% and 15% growth respectively in Q1. Red Hat and Watsonx are gaining traction among enterprise clients, nudging IBM toward a higher-margin platform model. The stock also found support from a broadened partnership with ServiceNow and new AI security offerings, which helped stabilise the shares after a sharp sell-off triggered by Accenture’s profit warning on June 18. That jolt knocked the entire IT services sector, dragging IBM from its early-June high to a trough near €227 before the chip news sparked a recovery.

Technically, IBM is testing a make-or-break level. The 200-day moving average sits at €235.79, just above Friday’s close. A clean breakout would open the path to the analyst consensus target of €258.85, implying roughly 10% upside. Below that, the stock has established a floor around the 50-day and 100-day averages at €217.50 and €217.07 respectively, which align with the 52-week low of €181.32 set in mid-May. The relative strength index reads 49.2 — neutral territory, leaving room for momentum in either direction.

The bearish counterpoint centres on structural risk. An IBM-commissioned study found that 91% of corporate executives do not fully understand their own AI dependencies. That lack of customer readiness lengthens the monetisation cycle and raises the odds that consulting revenue stays stuck in low single-digit growth. The Accenture episode was not an isolated shock; it reflected a broader hesitancy among enterprises either to pull the trigger on large AI projects or to rely less on external advisers as they adopt automation tools themselves.

The next real test comes in mid-July, when IBM reports second-quarter earnings. That report will show whether the €12.5 billion order book is starting to flow through the profit-and-loss statement. Until then, the stock is caught between a historic chip milestone and a consulting engine that has yet to regain its stride — a tension that makes the €235.79 level the most watched line on the chart.